SK33, a trifluoromethylated enobosarm analog, is a potent, and tissue selective anti-androgen. SK33reduces androgen receptor (AR) transcriptional activity. In Vitro In LNCaPAR+ cells, SK33, demonstrates a significantly potent activity with IC50=0.2 μM. SK33 decreases cells entering S-phase in LNCaP cells. Treatment of LNCaP/BicR cells with increasing concentrations of SK33 for 96 hours results in a dose-dependent response and an inhibition of cell growth, with IC50 of approximately 5 μM for SK33. MCE has not independently confirmed the accuracy of these methods. They are for reference only. Cell Viability AssayCell Line: LNCaP/BicR cells Concentration: 0.1-100 μM Incubation Time: 96 hours Result: Results in a dose-dependent response and an inhibition of cell growth. In Vivo SK33 (50 mg/kg; s.c.; 24 hours) inhibits AR transcriptional activity . MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model: ARE-Luc mice Dosage: 50 mg/kg Administration: Subcutaneously; 24 hours Result: Inhibited AR transcriptional activity. Form:Solid